Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inimex Pharmaceuticals and SARomics Biostructures have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1).
Subscribe to our email newsletter
Inimex Pharma claims IMX942 is the first of a new class of drugs known as Innate Defense Regulators (IDRs), which improve survival, ameliorate tissue damage and reduce bacterial infections through modulation of innate defenses.
SARomics Biostructures claims the crystal structure determined by the company provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
SARomics Biostructures chief scientific officer Derek Logan said they are very excited to be able to help Inimex Pharmaceuticals fully leverage the potential of IMX942 by revealing the molecular details of its interactions with its target protein.